N-(ARYLSULFONYL)-INDOLE-2-CARBOXAMIDE FBPASE INHIBITOR AND USE THEREOF

Title:

N-(ARYLSULFONYL)-INDOLE-2-CARBOXAMIDE FBPASE INHIBITOR AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2023/279280

Kind Code:

A1

Abstract:

Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical composition and a use thereof. Specifically, the present invention relates to an N-acylsulfonamide FBPase inhibitor and a salt thereof represented by general formula I and general formula II, a preparation method therefor, a composition containing one or more such compounds, a use of such compounds in the preparation of an FBPase inhibitor or a medicament for treating FBPase-related diseases, and a use thereof in the preparation of a drug for preventing and/or treating diabetes.

More Like This:

JPH1059936	NEW INHIBITOR OF METALLOPROTEASE, ITS PRODUCTION AND MEDICINAL COMPOSITION COMPRISING THE SAME
WO/2001/044226	SERINE PROTEASE INHIBITORS
JPS58103362	MANUFACTURE OF 4-HYDROXYINDOLE DERIVATIVE AND 4-OXO-4,5,6,7-TETRAHYDROINDOLE DERIVATIVE

Inventors:

XU BAILING (CN)
SHEN ZHUFANG (CN)
ZHOU JIE (CN)
LIU SHUAINAN (CN)
HU JINPING (CN)
JI WENMING (CN)

Application Number:

PCT/CN2021/104953

Publication Date:

January 12, 2023

Filing Date:

July 07, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

INST MATERIA MEDICA CAMS (CN)

International Classes:

C07D209/42; A61K31/404; A61K31/437; A61K31/4439; A61K31/496; A61K31/5377; A61P3/04; A61P3/10; A61P9/10; C07D235/24; C07D307/85; C07D333/70; C07D401/12; C07D405/12; C07D409/12; C07D413/12; C07D471/04

Foreign References:

CN107098846A	2017-08-29
CN1505613A	2004-06-16

Other References:

ZHOU JIE, BIE JIANBO, WANG XIAOYU, LIU QUAN, LI RONGCUI, CHEN HUALONG, HU JINPING, CAO HUI, JI WENMING, LI YAN, LIU SHUAINAN, SHEN: "Discovery of N -Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors—Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 18, 24 September 2020 (2020-09-24), US , pages 10307 - 10329, XP093021549, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00726

Attorney, Agent or Firm:

SHANGCHENG & PARTNERS (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHOD FOR TREATING TAIL GAS

Next Patent: DEVICE DISCOVERY METHOD AND APPARATUS, AND STORAGE MEDIUM